Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (89) clinical trials

IMCgp100-401 Rollover Study

IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible patients with advanced melanoma who have previously participated in an IMCgp100 study (parent study). Parent studies that are eligible for patients to continue to receive IMCgp100 in this rollover study must have completed and ...

Phase

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

At this time there is no experience concerning the sequencing strategy when using the two effective therapeutical approaches as targeting the Ras/Raf signalling pathway by BRAF and MEK inhibition or targeting immunologic checkpoint control with an antiPD-L1 antibody. This is a prospective, open, multicenter, randomized phase II study in patients ...

Phase

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-Mutated Metastatic Melanoma

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 study groups based on the type of mutation you have. If you are in Group A, you will receive nivolumab, dabrafenib, and trametinib (BRAF-mutated patients). If you ...

Phase

Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases

This study is an open label, single arm, phase II clinical trial of prospectively collected data evaluating efficacy and safety of nivolumab in metastatic melanoma patients with symptomatic brain metastases. It will be conducted in several study centers in the Netherlands. Patients with radiologic evidence of brain metastases and who ...

Phase

Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases

Study Drug Administration: If you are found to be eligible to take part in this study, you will receive atezolizumab by vein over 30-60 minutes (+/-10-15 minutes). Bevacizumab will then be given by vein over 30, 60, or 90 minutes (+/-10-15 minutes). You may be given standard drugs to help ...

Phase

Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases

Study Procedure: You will receive SRS on Day 1. There will be 1 day of treatment. You will sign a separate consent form for SRS that will explain the procedure and risks in detail. Study Visits: At 1, 6, and 9 months (+/- 14 days) after Day 1, the following ...

Phase

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Primary Objective: To determine the irRECIST* response rate of pembrolizumab with ipilimumab following initial progression or stable disease to anti-PD1/L1 antibody (or combination not containing anti-CTLA4) in subjects with advanced melanoma. Secondary Objective To summarize the progression-free survival (RECIST v1.1 and irRC) of the combination following prior treatment with anti-PD1/L1 ...

Phase

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma Merkel Cell Carcinoma or Other Solid Tumors

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Phase

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

While recent advances in the treatment of metastatic melanoma and NSCLC (non-small cell lung cancer) with agents targeting PD-1 are striking, there remains a significant need to develop therapies for patients with untreated brain metastases who were excluded from prior trials with MK-3475 and the majority of other studies in ...

Phase

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body. Eligible participants include those who have not received any systemic ...

Phase